HONG KONG, September 2026 — Health Gene Technologies (HGT) joined the fifth Hong Kong International Biotechnology Forum and Exhibition (BIOHK 2026), held Sept. 9–12 at the Hong Kong Convention and Exhibition Centre. The company exhibited the T2400 Sanger Sequencing Genetic Analyzer, its 24-capillary platform, at the shared booth of strategic partner GeneMind (Booth 3E-B14).
The show marked its fifth anniversary this year, opening with four days, 50-plus forums, and more than 10,000 participants from some 40 countries and regions. Against that backdrop, the GeneMind–HGT booth spent its first morning in steady conversation.
Two technologies, deliberately paired
The booth was arranged to tell one story end to end. GeneMind's NGS platforms read the genome at scale, surfacing candidate variants across infectious disease, oncology, and reproductive health applications. The T2400 picks up where that first read leaves off: a 24-capillary Sanger sequencing genetic analyzer with 8 fluorescence channels, built for both sequencing and fragment analysis — the step clinical workflows rely on to resolve the variants NGS flags but cannot fully characterize, from repeat expansions to copy-number variations.
Visitors could walk the booth in either direction; many left with the same conclusion. The two platforms are not competing generations but complementary halves of a complete genomic analysis workflow — one explores, the other confirms.
An industry audience, a market conversation
BIOHK's floor differs from an academic congress. Alongside researchers, it draws industry partners, distributors, and investors from across the Asia-Pacific — and that shifted the conversations at the booth from instrument capability to deployment: CE certification, reagent supply, and what it takes to bring gold-standard Sanger sequencing into clinical laboratories across Southeast Asia and beyond.
The four days also showed where the conversation is heading. Testing centers and third-party laboratories continue to treat Sanger as the gold standard — and that is the role the T2400 was built to hold. They saw the same advantages in PALACE, which runs on the T2400: broader coverage of human pathogens and microbes, and a shorter path to an answer than conventional methods offer. Beyond human health, new directions surfaced as well. The racing industry, for one, raised the prospect of applying PALACE to equine gastrointestinal health — an early opening for the platform in animal health. The takeaway, HGT said, is that capillary electrophoresis platforms are being pulled into markets well beyond their traditional clinical footprint.
Hong Kong, twice in a season
Fresh from August's FAOBMB congress at the University of Hong Kong, HGT was back in the city this month — a pace the company intends to keep. Hong Kong remains one of the Asia-Pacific's most connected life-science hubs, and HGT said it will continue working with partners such as GeneMind to keep NGS and Sanger sequencing genetic analyzer side by side in front of the region's research and clinical communities.
